非选择性β受体阻滞剂引起的门静脉压力降低可改善肝硬化伴或不伴腹水患者的预后并降低死亡率。
Portal pressure reductions induced by nonselective beta-blockers improve outcomes and decrease mortality in patients with cirrhosis with and without ascites.
作者信息
Turco Laura, García-Tsao Guadalupe
机构信息
1Internal Medicine Unit for the Treatment of Severe Organ Failure IRCCS Azienda Ospedaliero-Universitaria di Bologna Italy.
Section of Digestive Diseases Yale School of Medicine New Haven Connecticut USA.
出版信息
Clin Liver Dis (Hoboken). 2022 Jun 3;20(1):1-4. doi: 10.1002/cld.1210. eCollection 2022 Jul.
Abstract
Content available: Audio Recording.
摘要
提供的内容
录音。
相似文献
1
Portal pressure reductions induced by nonselective beta-blockers improve outcomes and decrease mortality in patients with cirrhosis with and without ascites.非选择性β受体阻滞剂引起的门静脉压力降低可改善肝硬化伴或不伴腹水患者的预后并降低死亡率。
Clin Liver Dis (Hoboken). 2022 Jun 3;20(1):1-4. doi: 10.1002/cld.1210. eCollection 2022 Jul.
2
The Beneficial Effect of Beta-Blockers in Patients With Cirrhosis, Portal Hypertension and Ascites.β受体阻滞剂对肝硬化、门静脉高压和腹水患者的有益作用。
Am J Med Sci. 2016 Feb;351(2):169-76. doi: 10.1016/j.amjms.2015.11.018.
3
Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis.降低门静脉压力可改善肝硬化患者（伴或不伴腹水）的预后：一项荟萃分析。
Clin Gastroenterol Hepatol. 2020 Feb;18(2):313-327.e6. doi: 10.1016/j.cgh.2019.05.050. Epub 2019 Jun 5.
4
Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis.β受体阻滞剂的短期血流动力学效应影响失代偿期肝硬化患者的生存率。
J Hepatol. 2020 Oct;73(4):829-841. doi: 10.1016/j.jhep.2020.03.048. Epub 2020 Apr 13.
5
Nonselective Beta-Blockers Do Not Affect Survival in Cirrhotic Patients with Ascites.非选择性β受体阻滞剂不会影响肝硬化腹水患者的生存率。
Dig Dis Sci. 2018 Jul;63(7):1737-1746. doi: 10.1007/s10620-018-5092-6. Epub 2018 May 3.
6
Cirrhosis and Portal Hypertension: How Do We Deal with Ascites and Its Consequences.肝硬化和门静脉高压症：我们如何处理腹水及其后果。
Med Clin North Am. 2023 May;107(3):505-516. doi: 10.1016/j.mcna.2022.12.004. Epub 2023 Feb 20.
7
Beta-adrenergic blockade in cirrhosis - harmful or helpful?肝硬化时的β-肾上腺素能阻断：有害还是有益？
Expert Rev Gastroenterol Hepatol. 2023 Jan-Jun;17(6):519-529. doi: 10.1080/17474124.2023.2215428. Epub 2023 May 26.
8
Nontumorous Portal Vein Thrombosis in Liver Cirrhosis: Possible Role of β-Blockers.非肿瘤性门静脉血栓形成在肝硬化中的作用：β-受体阻滞剂的可能作用。
Med Princ Pract. 2018;27(5):466-471. doi: 10.1159/000492893. Epub 2018 Aug 14.
9
Nonselective beta-blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study.非选择性β受体阻滞剂与肝硬化患者门静脉血栓形成风险：一项前瞻性纵向研究的结果。
Aliment Pharmacol Ther. 2019 Mar;49(5):582-588. doi: 10.1111/apt.15137. Epub 2019 Jan 22.
10
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.β 受体阻滞剂预防有临床显著门静脉高压症的肝硬化失代偿（PREDESCI）：一项随机、双盲、安慰剂对照、多中心试验。
Lancet. 2019 Apr 20;393(10181):1597-1608. doi: 10.1016/S0140-6736(18)31875-0. Epub 2019 Mar 22.
本文引用的文献
1
Baveno VII - Renewing consensus in portal hypertension.《巴韦诺 VII 共识：门静脉高压领域的新共识》
J Hepatol. 2022 Apr;76(4):959-974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30.
2
Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease.在非酒精性脂肪性肝病晚期，肝静脉压力梯度水平较低时可能发生失代偿，而在病毒性疾病患者中则不是这样。
Clin Gastroenterol Hepatol. 2022 Oct;20(10):2276-2286.e6. doi: 10.1016/j.cgh.2021.10.023. Epub 2021 Oct 21.
3
Can We Rely on Changes in HVPG in Patients with Cirrhosis?肝硬化患者的肝静脉压力梯度变化可靠吗？
Hepatology. 2021 Dec;74(6):2945-2947. doi: 10.1002/hep.32159. Epub 2021 Oct 28.
4
Test-Retest Reliability and Consistency of HVPG and Impact on Trial Design: A Study in 289 Patients from 20 Randomized Controlled Trials.肝静脉压力梯度（HVPG）的复测可靠性和一致性及其对试验设计的影响：来自 20 项随机对照试验的 289 例患者的研究。
Hepatology. 2021 Dec;74(6):3301-3315. doi: 10.1002/hep.32033. Epub 2021 Aug 15.
5
Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis.非酒精性脂肪性肝炎相关肝硬化中肝静脉楔压与门静脉压力之间的一致性
J Hepatol. 2021 Apr;74(4):811-818. doi: 10.1016/j.jhep.2020.10.003. Epub 2020 Oct 14.
6
Cardiodynamic state is associated with systemic inflammation and fatal acute-on-chronic liver failure.心脏动力学状态与全身炎症及致死性慢加急性肝衰竭相关。
Liver Int. 2020 Jun;40(6):1457-1466. doi: 10.1111/liv.14433. Epub 2020 Mar 30.
7
Portal Hypertension: Pathogenesis and Diagnosis.门静脉高压症：发病机制与诊断。
Clin Liver Dis. 2019 Nov;23(4):573-587. doi: 10.1016/j.cld.2019.07.007.
8
Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis.降低门静脉压力可改善肝硬化患者（伴或不伴腹水）的预后：一项荟萃分析。
Clin Gastroenterol Hepatol. 2020 Feb;18(2):313-327.e6. doi: 10.1016/j.cgh.2019.05.050. Epub 2019 Jun 5.
9
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.β 受体阻滞剂预防有临床显著门静脉高压症的肝硬化失代偿（PREDESCI）：一项随机、双盲、安慰剂对照、多中心试验。
Lancet. 2019 Apr 20;393(10181):1597-1608. doi: 10.1016/S0140-6736(18)31875-0. Epub 2019 Mar 22.
10
Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis.心肺血液动力学和 C 反应蛋白作为代偿性和失代偿性肝硬化的预后指标。
J Hepatol. 2018 May;68(5):949-958. doi: 10.1016/j.jhep.2017.12.027. Epub 2018 Jan 10.
Zotero 插件